New pharma takes spending lead

Posted 2 April 2024 AM

An immense spend by a rival has seen Roche lose its crown as the pharma spending the most on research and development, after nearly a decade at the top.

Last year MSD spent US$30.53 billion on research, more than half of its total revenue for the year. The sky-high sum is largely a result of previous deals, including its purchases of Prometheus and Imago for a combined US$11.4 billion. The pharma also spent US$5.5 billion on a collaboration with Daiichi Sankyo on three antibody-drug conjugates, which could get up to US$22 billion if all future sales milestones are met.

To see the whole article, please login